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Abstract
Transplantation of islet of Langerhans represents a viable therapeutic option for insulin-dependent diabetes mellitus.
Dramatic progress has been recently reported with the introduction of a glucocorticoid-free immunosuppressive regimen that
improved success rate, namely, insulin independence for 1 year or more, from 8% to 100%.
Ž The fate of islet grafts is determined by many concurrent phenomena, some of which are common to organ grafts i.e.
. rejection , while others are unique to nonvascularized cell transplants, including transplant cell mass and viability, as well as
nonspecific inflammation at the site of implant. Moreover, islet grafts lack clinical markers of early rejection, making it
difficult to recognize imminent rejection and to implement intervention with graft-saving immunosuppressive regimens.
In the present review, we will address the problems influencing islet graft success and the monitoring of islet cell graft
function. q2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
The field of cellular transplantation is rapidly
evolving and significant progress has been achieved
during the last two decades, largely due to improve-
ments in cell harvesting and purification techniques
and to the development of efficient and relatively
safe immunosuppressive regimens.
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October 2000, Vienna, Austria.
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Cell transplantation is intended to replace func-
tional tissue lost to infection, trauma, toxicity or
autoimmune destruction, and to restore or comple-
ment genetically dysfunctionalrdeficient cell popula-
tions, as in the case of inherited metabolic diseases
wx 1,2 . Advantages of cell transplantation, as com-
pared to whole-organ transplantation, are the rela-
tively safe and easy surgical techniques utilized in
the implantation procedures, and the potential for
manipulation of the graft in vitro prior to implant.
Since the first attempt of cell transplantation in
wx humans in the 15th century 3 , major progresses
have been made in developing methods that allow
for the harvesting of isolated cells from different
organs, while preserving their viability and function
wx 4 . The introduction of enzymes that allow efficient
cell separation while preserving cellular functional
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characteristics, opened the way for the development
of procedures for cell isolation from various organs
and eventual transplantation of purified cell suspen-
wx sions 5,6 .
A variety of cells are currently used in clinical
transplantation and even more potential sources are
under evaluation for possible future clinical applica-
Ž tion. Transplantation of bone marrow cells hema-
topoietic malignancies, tolerance induction, and auto-
.Ž . immune diseases , hepatocytes metabolic disorders ,
Ž islets of Langerhans insulin-dependent diabetes mel-
.Ž litus, IDDM , chondrocytes articular cartilage de-
.Ž fects , neural cells chronic pain, spinal cord injury,
. Parkinson’s and Huntington’s diseases are examples
of models studied worldwide.
New emerging applications aiming at solving the
shortage of organs and improving engraftment in-
clude the use of xenogeneic tissues, tissue regenera-
tion from stem cells, gene therapy, and immuno-
wx modulation 2 .
The fate of cellular grafts is determined by many
concurrent phenomena, some of which are common
Ž to organ grafts i.e. rejection, recurrence of disease,
. and ischemiarreperfusion injury , while others are
unique to nonvascularized cell implants, including
transplanted cell mass and viability, and nonspecific
inflammation at the site of implant that might lead to
early loss of function.
Most cellular grafts lack clinical markers of early
rejection, often because it is cumbersome to gain
access for biopsies or other diagnostic techniques,
making the recognition of imminent rejection diffi-
cult, and the implementation of intervention with
rescue immunosuppressive regimens practically im-
possible.
The present review will focus on transplantation
of islets of Langerhans as a paradigm of cell trans-
plantation. We will briefly discuss the factors influ-
encing islet graft success, and the ways of monitor-
ing graft function.
2. Islet of Langerhans transplantation
The main indication for islet transplantation is
type 1 diabetes mellitus, the result of a selective
autoimmune destruction of insulin-producing b cells
wx 7,8 . IDDM patients require replacement therapy
with exogenous insulin, and often develop chronic
complications, including nephropathy, neuropathy,
retinopathy, and micro- and macrovascular angiopa-
thy, that can profoundly affect their quality of life.
Maintenance of near-to-normal blood glucose lev-
els by intensive insulin therapy is a valuable ap-
proach for the prevention or delay of the dreaded
wx long-term complications of diabetes 9 , although
often characterized by a lack of or scarce compliance
from patients and by frequent life-threatening hypo-
glycemic episodes.
Transplantation of insulin-producing tissues, on
the other hand, has proven, when successful, to be
capable of maintaining excellent metabolic control in
the absence of hypoglycemia.
Endocrine tissue replacement by whole-organ
pancreas transplantation, while allowing for long-
term glucose metabolic control, insulin independence
in the absence of hypoglycemic episodes, and rever-
wx sal of diabetic complications 10 , is often associated
wx with significant morbidity and mortality rates 11,12 .
Islet cell transplantation, on the other hand, pre-
sents the remarkable advantage of a fast and easy
procedure of implant: islets are injected into the liver
by percutaneous transhepatic catheterization of the
portal vein, with a relatively minimal perioperative
wx risk and morbidity 13 .
The procedure is mainly performed in type 1
diabetic patients with end-stage renal failure, as a
Ž. simultaneous islet-kidney SIK or as an islet-after-
Ž. wx kidney IAK transplant 13,14 . Islet transplantation
is also performed after pancreatic graft failure, since
whole-organ pancreas retransplants are associated
with an elevated rate of failure. Islet autotransplanta-
tion can prevent pancreatectomy-induced diabetes in
case of extended pancreatic resection for benign
wx disease 15,16 . Allogeneic islet transplantation can
also be performed in patients affected by pancreatec-
wx tomy-induced diabetes 17–21 . AInsulin-requiring
wx diabetes,B secondary to cystic fibrosis 22 and
wx hemochromatosis 23 , represents a further indication
for islet transplantation, sometimes combined to lung
or liver transplant procedure. Islet transplantation for
type 2 diabetes has been attempted in very few cases
wx in pilot trials 24,25 . Transplantation of islets alone
Ž. ITA in patients with functioning kidneys is at
present limited to cases of brittle type 1 diabetes
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episodes, or with uncontrolled diabetes despite com-
pliance with insulin regimen. In these patients, the
risks associated with global metabolic instability are
considered severe enough to justify islet transplanta-
wx tion and chronic immunosuppression 26 .
Although the first attempts of endocrine replace-
wx ment were reported in the 1890s 27,28 , research in
islet transplantation has evolved rapidly only after
the 1960s, with the introduction of improved meth-
ods for islet isolation and transplantation techniques
wx 29–36 . Those improvements led to the first islet
wx transplant in a type 1 diabetic patient in 1974 37 . In
the late 1980s, after the introduction of new
immunosuppressive agents such as cyclosporine-A
and tacrolimus, the clinical application and fre-
quency of islet transplantation increased worldwide,
with the occasional achievement of insulin indepen-
wx dence 13,14,38 and some cases of long-term graft
Ž survival ascertained by the presence of detectable
. C-peptide levels , with improved metabolic control
wx 39 .
Since islet transplantation has been considered an
experimental procedure characterized by marginal
success, it has historically represented an option
Ž when combined to other organ transplant e.g., SIK
. or IAK , to justify the use of chronic immuno-
suppression. The immunosuppressive protocols uti-
lized in the past years included monoclonal or poly-
Ž clonal T-cell antibody such as ALG, ATG, OKT3,
. or anti-CD4 -based induction immunosuppression,
and triple-drug maintenance therapy based on glu-
cocorticoids, cyclosporine or tacrolimus, and aza-
wx thioprine or mycophenolate mofetil 13,14 . Un-
fortunately, most of the immunosuppressive drugs
Ž. glucocorticoids and calcineurin inhibitors are
wx known to exert toxic effects on the islet b cells 40
wx or to induce insulin resistance 41 . Furthermore, the
antirejection protocols commonly used for solid or-
gan transplantation may have detrimental conse-
quences on islet graft fate.
The International Islet Transplant Registry re-
ported that a total of 405 adult islet allogeneic
transplants were performed from 1893 through 1998
wx 14 . Analysis of 200 C-peptide negative type 1
diabetic patients transplanted from 1990 through 1997
showed a cumulative 1-year patient survival of 96%,
Ž and graft survival assessed by measurable basal
. C-peptide levels above 0.5 ngrml of 35%, with
insulin independence at 1 year in only 8% of the
wx recipients 14 . Insulin independence rate was higher
in patients receiving multiple-donor islet prepara-
Ž. tions 15r77, 19% , when compared to those receiv-
Ž. ing single-donor preparations 14r123, 11% , re-
flecting the need for a conspicuous islet graft mass
Žhigher than 6,000 islet equivalents per kilogram of
. recipient’s body weight .
wx The results reported recently by Shapiro et al. 26
on the successful series of allogeneic ITA in type 1
diabetic patients treated with a glucocorticoid-free
immunosuppression protocol, including a short
course of anti-IL2 receptor antibody, and mainte-
nance therapy based on rapamycin and low dose of
Ž. tacrolimus ‘Edmonton protocol’ , represent a major
breakthrough in the field showing that it is possible
to achieve reproducible insulin independence and
good glucose metabolic control, opening a new era
in islet transplantation. All patients received islets
Ž isolated from more than one donor two to three
. grafts , in order to obtain an islet mass sufficient to
Ž achieve insulin independence 11,547"1,604 islet
equivalents per kilogram of recipient’s body weight
wx 26 . Although infusion of islet from a single donor
did not result in insulin independence, all the patients
had improved glycemic control, reduced insulin re-
quirement, and absence of hypoglycemic episodes
wx soon after receiving the first graft 26 .
Despite the successful results of the ‘Edmonton
protocol,’ the need for more than one organ per
recipient to achieve insulin independence represents
a major hurdle to be solved, due to the shortage of
organs. A likely explanation of the need for multiple
donors is the destruction of a substantial mass of
islets immediately after transplantation. Early loss of
implanted islets is due to their susceptibility to mi-
croenvironment alteration with consequent functional
impairment and loss to apoptosis.
Also, the need for chronic immunosuppression
limits the option of ITA to a small cohort of patients,
preventing its implementation earlier after diabetes
onset in order to prevent the occurrence of the
long-term complications of hyperglycemia. Immuno-
suppressive protocols are frequently modified ac-
cording to the availability of new molecules, and
several strategies are at present under evaluation,
aiming at improving graft acceptance andror induc-
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wx use of bone marrow cells 47–49 are examples of
such strategies.
3. Factors influencing islet graft function
Several factors contribute to islet cell engraftment
and function. The number of islets implanted is a
critical factor in obtaining complete function, and
depends upon the condition of the organ donor, the
procurement and preservation of the pancreas, and
the procedure and reagents used during isolation and
purification. All these variables influence yield and
Ž. quality purity and viability of the graft, making it
difficult to completely standardize the procedures.
Early after transplantation, islets are denervated, not
yet vascularized, implanted into a new microenviron-
ment in the absence of extracellular matrix, and
exposed to nonspecific inflammatory events occur-
ring at the site of implant. These are all conditions
that might result in functional impairment. After
engraftment, islets are exposed not only to allorecog-
nition and rejection, but also to recurrence of autoim-
Ž. munity type 1 diabetes . Furthermore, immuno-
suppressive drugs might also exert some toxicity on
islet b cells, impairing their function.
3.1. Organ procurement and islet isolation
Several parameters influence the course and suc-
cess of pancreatic islet isolation. The quality and
quantity of islets obtained from a pancreas depend
upon events occurring before, during and after pan-
wx creas procurement 50–54 .
Endocrine tissue is dispersed throughout the ex-
ocrine pancreas as cell clusters representing about
wx 1% of the total mass of the gland 55 ; obtaining islet
preparations with 50–90% purity therefore implies
wx that a 50–90-fold enrichment is obtained 56 . The
purification method determines the mass and viabil-
ity of the islets, as well as their contamination level
wx potentially influencing their immunogenicity 57–59 .
Purification, furthermore, is required in order to
wx minimize the volume of tissue to be implanted 60 .
The islet isolation procedure consists of a mecha-
nically enhanced enzymatic digestion process that
allows for the release of the islets from their sur-
rounding connective and exocrine tissue, without
wx destroying their integrity 36,61 . The purification
process follows, where islets are separated from
contaminating nonendocrine tissue, via centrifuga-
wx tion on density gradients 56,62 .
The isolation procedure itself might influence
Ž. yield and quality purity and viability of the final
wx islet preparation 56 . There is evidence that the lack
of native extracellular matrix components and of
selected growth factors is involved in triggering islet
w programmed cell death in experimental models 63–
x 65 .
Endotoxin contamination of the reagents needed
for islet isolation has been suggested as a major
contributing factor in the occurrence of early graft
wx loss 61,63,66–70 . Endotoxin could play a detrimen-
tal role on islet function by stimulating a variety of
Ž resident cell types i.e. macrophages, endothelial cells
. and endocrine cells , during the isolation process.
Also, direct binding of endotoxin to b-cells express-
wx ing CD14 has been hypothesized 70,71 , and could
concur in damaging the islets. Cytokine production
Ž elicited by endotoxin stimulation e.g., IL1b, TNFa,
. and IL6 may lead to apoptosis or destruction of the
endocrine cells through the release of cytotoxic me-
wx diators such as free oxygen radicals 70,72,73 .
By the time islets are transplanted, endotoxin has
induced overexpression of adhesion and MHC
Ž. molecules L. Inverardi, unpublished data . Addi-
tionally cytokines, along with some residual endo-
toxin, are likely to be carried to the graft site, all of
which may lead to additional activation of host
wx effectors cells 70 .
3.2. Islet mass implanted and microenÕironment
The mass of transplanted islets plays an important
wx role in determining the function of the graft 74–76 .
Standardization of the isolation procedure can lead to
wx improved yield from a single donor 36,62,77 , but
also the management in the peritransplant period
wx 78,79 is important in prevention of early islet graft
failure.
Islets are transplanted into the liver via the portal
vein. They lack physiological extracellular matrix,
vascularization, and innervation. It is conceivable
that a sizable fraction of the implanted islet mass
might be lost due to hypoxia early posttransplant
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wx revascularization 81 . Early after implant, islets are
also exposed to nonspecific inflammatory events with
macrophage activation that might profoundly impair
the mass of the islet graft and lead to early loss of
wx function 82,83 , as well as amplify the subsequent
wx specific immune response 84 . Microenvironment
activation and carry-over of heterologous proteins
and endotoxin have been postulated to represent
major contributors to this inflammatory process
wx 66,68,70 . Proinflammatory cytokines and oxygen
radicals produced in situ might in fact exert deleteri-
ous effects on the implanted islet b cells that are
exquisitely sensitive to inflammation and oxidative
wx stress 85–93 . Possible consequences of this local
perturbation are the functional impairment of islet b
cells resulting in altered glucose-stimulated insulin
release, and induction of apoptosis, phenomena that
can contribute to graft failure. Complement activa-
tion has also been associated with islet graft failure,
both in the presence of antibody binding to islet
wx alloantigens 94–96 , and via direct binding to ex-
wx posed extracellular matrix proteins 97 .
Different strategies aiming at protecting islet cells
from early loss due to nonspecific inflammation, by
either conferring cytoprotection andror reducing the
effects of microenvironment activation, have been
suggested to improve graft function and might allow
for the use of only one donor organ per recipient
ww x x Refs. 70,79,83,98,99 , and our unpublished data .
The intrahepatic site of implantation does not
provide the islets with physiological regulation of
glucose metabolism. Experimental data suggest that
endogenous glucose production is incompletely in-
hibited by intrahepatic islet grafts, in contrast to
wx grafts with portal delivery of islet secretions 100 .
This might be the consequence of the fact that
intrahepatic islet b cells receive inhibitory signals
from pancreatic glucagon, somatostatin, and nor-
adrenaline secreted upstream and carried throughout
wx the portal vein 101 . However, it has also been
reported that intraportal islet transplantation im-
proves sympathoadrenal glucose counter regulation
and neurogenic symptom recognition in recipients
wx with longstanding type 1 diabetes 102 , with no
glucagon response to hypoglycemia posttransplant.
Normal pancreatic islets are mainly supplied with
extrinsic innervation via the splanchnic and vagus
nerves and insulin-secreting b cells are influenced
wx by neuropeptides and classic transmittors 103 . Hor-
monal secretion from islets in their normal environ-
ment is controlled by nutrients in the blood, hor-
w mones, and by the autonomic nervous system 103,
x 104 . The current working hypothesis of the mecha-
nisms of insulin release is that food intake activates
insulinogenic parasympathetic nerves, whereas stress
may elicit a sympathetic input that depresses insulin
wx secretion 103,105 . After implant islets display
altered insulin secretory dynamics in response to
wx w x glucose 106 and neurotransmitters 107–109 , sug-
gesting a dysfunctional reaction of the b cells to
denervation andror the alien microenvironment
wx 103 . A process of reinnervation follows the implant
where fibers of both intrinsic and extrinsic origin are
involved and which is characterized by dynamic
wx changes in expression of neuropeptides 103 . In the
near future, further data in this specific area of
research will provide additional important informa-
tion on the physiology of transplanted islet cells. The
lack of the vagus-induced cephalic phase of insulin
wx release in intrahepatic implanted islets 110 is con-
sistent with what has been observed in the dener-
wx vated pancreas 111 , suggesting that denervation
wx might be the reason of the observed anomaly 112 .
3.3. Recurrence of autoimmunity
It is commonly accepted that autoimmunity per-
wx sists long after the onset of diabetes 113,114 . Islets
transplanted into patients with autoimmune diabetes
might be lost due to recurrence of the disease despite
the immunosuppressive treatment. The pattern of
infiltration with selective destruction of islet b cells
allows for the differentiation between recurrence of
autoimmunity and the occurrence of allorejection.
This phenomenon was first described in identical
wx twin donor pancreas transplants 113,115 and was
reconfirmed in experimental models of autoimmune
wx diabetes 116–118 . Autoimmune destruction of
transplanted islets seems to be quite resistant to
w commonly used immunosuppressive drugs 119–
x 123 . An interesting recent finding suggests a protec-
tive role for donor-derived immunomodulatory cell
subsets, since irradiation of donor pancreas trans-
plants abrogates the protection of whole-pancreas
wx grafts from recurrent autoimmunity 123 , whereas
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destruction if donor pancreatic lymph node cells are
wx included in the graft 122 .
The presence before transplant of measurable titers
of anti-islet autoantibodies has been correlated with
the loss of graft function both in islet and whole-pan-
creas transplantation, and an increase in autoantibody
titer after transplant has been suggested as an early
w marker for the recurrence of autoimmunity 124–
x 127 . Further evidence of this relation needs to be
obtained.
3.4. Rejection
Allograft rejection is a common problem in organ
and tissue transplantation. The availability of new
immunosuppressive drugs and the development of
combinatorial protocols have dramatically improved
the outcome of allogeneic organ grafts. In the case of
cellular grafts, like islets of Langerhans, the lack of
specific markers, allowing the monitoring and detec-
tion of recurrence of autoimmunity andror occur-
rence of rejection, makes it difficult to establish
appropriate rescue immunosuppressive intervention
capable of prolonging islet graft survival. It is con-
ceivable that islet graft loss is mostly due to the
coinciding occurrence of both autoimmunity and al-
lorejection.
4. Monitoring of islet graft function
Monitoring of islet graft function is based on the
measurement of blood glucose and glycosylated
Ž. hemoglobin HbA1c levels, basal and peak C-
peptide response to stimulation, and required exoge-
nous insulin administration. Metabolic tests can be
performed that provide detailed information on the
performance of the transplanted islet cells to secreta-
gogue stimuli. The immunological monitoring of
autoimmunity recurrence and graft rejection, on the
other hand, is quite difficult. The peculiarities of site
of implant and the very nature of the cell graft make
access for serial biopsies or imaging diagnostic
methods practically impossible. This scenario is fur-
ther complicated by the lack of standardized markers
of rejection or recurrence of autoimmunity. Very
often impaired function is diagnosed at the occur-
rence of hyperglycemia that is associated with the
loss of most of the islet graft mass, rendering vain
rescue treatments.
4.1. Glycemic control
The extent of mean fluctuations in serum glucose
concentrations, measured as mean amplitude of
glycemic variation in the 24-h period is a useful tool
wx in the assessment of metabolic instability 26,128 .
The results obtained with the ‘Edmonton protocol’
showed dramatic improvement following sequential
Ž. ITAs to reach a sufficient islet mass with decreased
overall mean serum glucose concentrations, mean
amplitude of glycemic variations, and lability of
wx glycemic control in a 24-h period 26 .
Measurement of fasting and postprandial blood
glucose in allogeneic islet transplant performed in
nonhuman primates showed that postprandial hyper-
glycemia precedes elevations in fasting blood glu-
wx cose 42 . In this model, an increase in fasting blood
glucose levels higher than 100 mgrdl andror post-
prandial levels higher than 150 mgrdl in recipients
with previously stable glucose values could be con-
wx sidered an early marker of rejection 42 .
4.2. Insulin requirement
Insulin requirement inversely correlates with glu-
cose metabolic control. The goal of successful islet
transplantation is the achievement of a status of
wx normoglycemia and insulin independence 129 . From
data provided by the Islet Transplant Registry, it is
shown that insulin independence in type 1 recipients
of allogeneic islets at 1-year posttransplant follow-up
is hard to achieve, being observed in less than 10%
wx of the cases 13,14 . In the data of the Edmonton
group the success rate rose up to 100%, with all
patients off exogenous insulin therapy after receiving
the last islet graft and, maintaining insulin indepen-
wx dence at 1-year follow-up posttransplant 26 .
While obviously inversely correlated with the
mass of functionally competent islets, insulin re-
quirement does not represent a viable early rejec-
tionrrecurrence marker.
4.3. C-peptide leÕels
Islet grafts are considered partially successful
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detectable in C-peptide pretransplant negative pa-
Ž. tients plasma C-peptide levels -0.2 ngrml that
remain insulin-dependent posttransplant. C-peptide
and insulin are produced in equimolar amounts from
the proinsulin molecule by pancreatic b cells, and
measurement of plasma C-peptide allows monitoring
of b cell function when the patient is treated with
exogenous insulin.
Persistent C-peptide secretion several years after
transplant in type 1 diabetic recipients has been
correlated with long-term normalization or near-nor-
malization of blood glucose control, and significant
improvement of HbA1c levels in the absence of
wx severe episodes of hypoglycemia 13,39 .
4.4. Glycosylated hemoglobin
Ž. Hemoglobin A1c HbA1c is formed from the
irreversible nonenzymatic glycation of the hemoglo-
bin b chain, and is directly proportional to the
ambient glucose concentration. The level of HbA1c
highly correlates with blood sugar levels and lasts
longer after the maximum blood sugar level is ob-
served, making it a more reliable long-term marker
of blood sugar level control than immediate glycemia
wx measurement 130,131 . The semiological value of
HbA1c as a retrospective and cumulative marker of
glycemic balance in diabetic patients has been con-
wx firmed by epidemiological studies 9,132,133 . In the
case of intensive insulin therapy, the desired end
result is a glycemic level slightly higher than normal,
to prevent hypoglycemic episodes. In the long-term,
however, this might result in delay, and not preven-
tion, of the occurrence of complications. Successful
islet transplantation improves the glucose metabolic
control with return of HbA1c levels within the nor-
wx mal range 26 . Also, in long-term functioning islet
grafts, the achievement of improved glucose
metabolic control was associated with normalization
of HbA1c during the first 2 years after transplanta-
tion, and normal or near-normal levels over a 6-year
period, in conjunction with small dosage of exoge-
nous insulin and in the absence of hypoglycemic
wx episodes 39 . Because of the cumulative nature of
this marker, it does not represent a good means of
monitoring short-term alteration in islet function and,
therefore, it is not a valuable early marker of graft
rejectionrautoimmune recurrence.
4.5. Oral glucose tolerance test
Glucose tolerance tests are utilized to assess islet
b cell function in response to stimuli: basal and peak
insulinrC-peptide levels are expressed as an index.
Ž. The oral glucose tolerance test OGTT consists of
Ž the administration of 6 kcalrkg Sustacal 140 grl
carbohydrates, 24 grl fat, and 61 grl protein; 1
. kcalrml and calculation of the stimulation index
wx between basal and peak C-peptide levels 39,134 .
When glucose tolerance tests are performed in
Ž. patients with only one kidney SIK or IAK , it is
important to consider that C-peptide half-life is pro-
wx longed by about 40% 23,135 , rendering difficult the
use of C-peptide as measurement of insulin produc-
wx tion 39 .
In patients in whom insulin independence has
been achieved after ITA, OGTT might reveal impair-
wx ment of function 26 .
Although a viable means of monitoring islet func-
tion, OGTT is not performed with high frequency,
limiting the possibility of early detection of graft
impairment.
4.6. IntraÕenous glucose tolerance test
It has been reported that the first-phase insulin
release in response to intravenous glucose tolerance
Ž. testing IVGTT provides an accurate reflection of
wx islet b cell mass 42,136 , and its use is valuable in
the long-term monitoring of the islet graft mass after
Ž transplant. It consists of the infusion of glucose 0.3
. grkg body weight, over 1 min and collection of
serial samples of arterial blood before and after
injection for C-peptide determination. Stimulation
Ž. with tolbutamide 300 mg follows 20 min later and
the stimulation index of insulin secretion is calcu-
wx lated 39 . Similarly to OGTT, this assay cannot be
performed frequently as it would be needed to repre-
sent a viable marker of early graft failure.
4.7. Clamp studies
In the clamp technique an apparent steady state of
the blood glucose is obtained and maintained for the
duration of the experiment. This allows for defining
Ž. the effect of a stimulus e.g., insulin infusion under
wx homeostatic glucose levels 137 . The hyperinsuline-() A. Pileggi et al.rClinica Chimica Acta 310 2001 3–16 10
mic, euglycemic clamp technique has been used to
assess whole blood insulin sensitivity in different
ww x x pathophysiological conditions reviewed in 101 ,
and has allowed researchers to demonstrate that basal
hepatic glucose production is nearly normal in pa-
wx tients with functional islet grafts 138 and whole-
wx pancreas grafts 139 . Also, a positive correlation
between basal hepatic glucose output and prednisone
administration has been ruled out, indicating the
detrimental effects of the drug on glucose homeosta-
wx sis 138 . Furthermore, it has been reported that
intrahepatic islet grafts improve sympathoadrenal
glucose counter regulation and neurogenic symptom
recognition in recipients with longstanding type 1
diabetes, with no glucagon production in response to
wx hypoglycemia posttransplant 102 .
The clamp technique allows for the studying of
the effects of the nonglucose secretagogue arginine
wx on insulin and glucagon secretion 140–143 .
Once again, this test is of no value to predict or
diagnose rejection, while it is of great value in
functional assessment.
5. Monitoring of autoimmunity
Standardized markers for monitoring the autoim-
mune response to transplanted islets are not available
to date. Analysis of humoral autoimmune response,
such as monitoring of autoantibodies titers, has been
proposed. A correlation between the rising of titer
of antibodies directed at glutamate decarboxylase
Ž. Ž . GAD 65 and tyrosine phosphatase IA-2 , and graft
loss due to recurrence of autoimmunity has been
wx reported in whole-pancreas transplantation 124,125 .
Furthermore, progressive islet graft failure has been
observed earlier in autoantibody-positive than in au-
toantibody-negative recipients of intrahepatic islet
wx allografts 126,127 . Further studies are necessary to
establish the predictive value of these antibodies for
delineating the recurrence of autoimmunity.
Also, monitoring of islet graft-specific cellular
auto- and alloreactivity in peripheral blood has been
suggested as a valuable tool to better understand the
mechanisms influencing islet allograft survival in
wx diabetic patients 144,145 . In vitro assaying of the
proliferative response of T lymphocytes to certain
Ž islet autoantigens GAD65, insulin, insulin-secretory
granules, ICA69, h38kD, r38kD, insulinoma mem-
.Ž branes and control stimuli bovine serum albumin,
. aB-cystallin, tetanus toxoid has been proposed for
the detection of changes in the recipient autoimmune
reactivity that might correlate with graft outcome
wx 144 ; the predictive value of such parameters to
assess cell-mediated autoimmunity recurrence awaits
further confirmation.
6. Monitoring of rejection
Early markers of rejection of islet allografts are
not yet available. It is cumbersome to obtain infor-
mation by performing serial biopsies for histological
analysis, or by using imaging analysis. Often the
diagnosis is done at the occurrence of hyper-
glycemia, when a conspicuous mass of islet has
already been lost, making vain attempts at graft
rescue through antirejection treatments.
A correlation between islet allograft failure and
increased titers of antidonor HLA antibodies has
been reported, measured by panel reactive antibody
wx testing 146 .
Considerable progress in developing a molecular-
based diagnostic approach to define early markers
for rejection has recently been made, and quantita-
tive analysis of the genes involved in the cytolytic
Ž machinery of cytotoxic T-lymphocytes including
. granzyme B, perforin, and Fas ligand in the periph-
eral blood has been proposed as an approach to
detect early episodes of rejection and drive antirejec-
wx tion therapy 147–149 .
Alloreactivity assayed by cytotoxic T lymphocyte
precursors and T-helper frequencies against all mis-
matched HLA antigens of islet donors might allow
for the differentiation between the occurrences of
wx auto- or alloreactivity 144 . A similar approach has
been reported in experimental islet transplantation to
monitor the occurrence of allorejection by perform-
wx ing serial mixed lymphocyte-islet coculture 150 .
7. Future directions
In the monitoring of graft function, the develop-
ment of early markers of rejection andror tools to
monitor the autoimmune response will be of corner-
stone importance to implement interventions with
antirejection therapies preventing graft loss.() A. Pileggi et al.rClinica Chimica Acta 310 2001 3–16 11
The frequent need for more than one organ in
order to reach an islet mass sufficient to achieve
insulin independence represents a major hurdle in
view of the shortage of human organs. One approach
is the expansion of the donor pool, possibly with
educational programs targeting selected population
sects, physicians, and health institutions. On the
other hand, this problem has generated a variety of
lines of research, including the use of xenogeneic
wx w x sources 151 , gene therapy 152,153 , in vitro ma-
w nipulation of the graft to confer cytoprotection 154–
xw x 157 , expansion of b cells 158 , and b cells regen-
wx eration from stem cells 159 .
The need for chronic immunosuppression is an-
other hurdle that limits the extension of islet trans-
plantation to a larger number of patients affected by
type 1 diabetes mellitus. While successful ITA may
confer insulin independence and good metabolic con-
trol that might prevent the occurrence of long-term
complications, the use of chronic immunosuppres-
sion might expose the patients to the complications
Ž related to the drugs e.g., posttransplant malignan-
. cies, infections . Several approaches aiming at the
induction of immunological tolerance are under eval-
uation worldwide, including the use of immuno-
modulation and the transplantation of donor-specific
bone marrow cells to achieve stable hemopoietic
chimerism, thus possibly allowing discontinuation of
immunosuppression.
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